Le Lézard
Classified in: Health
Subject: PER

Nitto Avecia Pharma Services Appoints Raymond Kaczmarek as President


IRVINE, Calif., Jan. 15, 2018 /CNW/ -- Nitto Avecia Pharma Services, Inc. (Avecia Pharma), a leading CGMP contract development and manufacturing organization (CDMO), announced today that it has appointed Raymond Kaczmarek to the position of President. Mr. Kaczmarek will have full P&L responsibility for the entire organization.

Nitto Avecia Pharma Services

Detlef Rethage, President of parent company, Nitto Denko Avecia, Inc., stated, "We are excited to welcome Ray to Avecia Pharma. We are confident that with his proven leadership, knowledge and experience in a broad spectrum of drug development activities, Ray will continue to further strengthen and grow the business and meet the needs of our clients."

Mr. Kaczmarek joins the organization with nearly 20 years of extensive experience in operations management within the pharmaceutical and biopharmaceutical industries. He most recently served as Vice President, Commercial Manufacturing and Supply Operations at Pacira Pharmaceuticals, Inc., located in San Diego, California. His proven leadership in strategic manufacturing management, for both clinical and commercial manufacturing, makes him perfectly suited to contribute to the future success of the company. In addition to working for Pacira, Mr. Kaczmarek has held management positions in such companies as Bayer Biologics, Abbott Laboratories, Boehringer-Ingelheim, Covidien, Athersys, and Wyeth Biotech.

Mr. Kaczmarek explained, "It is truly a privilege to lead this wonderful team at Avecia Pharma as we continue to enhance its capabilities as a full service CDMO.  I look forward to our future development of the Irvine campus, strengthening our service capabilities, and above all, providing outstanding outcomes for our clients."

Mr. Kaczmarek earned a Bachelor of Science degree in Biology from Virginia Polytechnic Institute and State University (Virginia Tech).  He is also a proud veteran who served our country as a combat engineering officer in the US ARMY Corps of Engineers.

ABOUT NITTO AVECIA PHARMA SERVICES INC.
Nitto Avecia Pharma Services is your single solution for premier contract development and manufacturing services. Nitto Avecia Pharma Services supports the pharmaceutical, biopharmaceutical, and medical device industries with a complete package of CGMP services including pre-formulation/formulation, parenteral manufacturing, analytical development, biopharmaceutical development, structural chemistry, analytical chemistry, microbiology, stability storage and drug delivery device testing. With three state-of-the-art facilities located on one campus in Irvine, CA. Learn more at www.aveciapharma.com

ABOUT NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc. is a recognized leader in manufacturing and development services of oligonucleotide therapeutic with facilities located in Milford, MA.; Marlboro, MA.; and Cincinnati OH offering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg + post commercial launch. More information: www.Avecia.com. Nitto Denko Avecia is proud member of Nitto Group. More information: www.Nitto.com

 

SOURCE Nitto Avecia Pharma Services


These press releases may also interest you

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

at 17:31
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...

at 17:00
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings. SONIFI Health is a leading U.S. healthcare technology company based in Sioux...



News published on and distributed by: